Compare · BDX vs PRCT
BDX vs PRCT
Side-by-side comparison of Becton Dickinson and Company (BDX) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 50.8x PRCT ($1.04B).
- Over the past year, BDX is up 1.4% and PRCT is down 46.8% - BDX leads by 48.1 points.
- BDX has been more active in the news (9 items in the past 4 weeks vs 6 for PRCT).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- PROCEPT BioRobotics Corporation
- Price
- $191.68-1.09%
- $17.57-3.17%
- Market cap
- $52.78B
- $1.04B
- 1M return
- +5.72%
- -9.76%
- 1Y return
- +1.38%
- -46.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest PRCT
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
- Barclays initiated coverage on PROCEPT BioRobotics with a new price target
- SEC Form 4 filed by PROCEPT BioRobotics Corporation
- SEC Form 3 filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- EVP, CLO, CORP. SEC. Nouri Alaleh sold $6,223 worth of shares (297 units at $20.95), decreasing direct ownership by 0.23% to 127,737 units (SEC Form 4) to cover withholding tax
- EVP, Chief Technology Officer Templin Barry L sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.39% to 94,826 units (SEC Form 4) to cover withholding tax
- EVP, CFO Waters Kevin sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.21% to 180,355 units (SEC Form 4) to satisfy withholding tax
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026